Literature DB >> 12745495

Efficacy of oral transmucosal nicotine lozenge for suppression of withdrawal symptoms in smoking abstinence.

Myra L Muramoto1, James Ranger-Moore, Scott J Leischow.   

Abstract

Nicotine replacement therapy relieves withdrawal symptoms, significantly improving smoking cessation rates. Oral transmucosal nicotine (OT-NIC) is a novel nicotine delivery system consisting of a lozenge (OT-NIC unit) containing 4 mg of nicotine, which is dissolved in the cheek pouch, releasing nicotine for absorption through the buccal mucosa. Theoretical advantages of OT-NIC include that it does not require special chewing methods or interfere with dental work, it provides sensory oral effect, and it can be dosed to effect. This study aimed to determine the preliminary safety and efficacy of OT-NIC for suppression of nicotine withdrawal symptoms over 8 days of smoking abstinence and to assess flavor preference, sensory characteristics, and acceptability. In an open-label, within-subjects design, 11 smokers used three different flavors of OT-NIC ad lib in response to withdrawal symptoms and craving. On days 1 and 8, withdrawal symptoms were measured with pre- and postadministration scores for each of the first three OT-NIC units used (three different flavors presented in random order). Flavor preference, desire to smoke, sensory characteristics, acceptability, and overall OT-NIC performance were rated at the end of each day. A generalized estimating equation analysis was conducted to account for the repeated-measures design. Use of OT-NIC resulted in a significant decrease in a composite withdrawal score aggregating scores from all eight symptoms (decline of.57 units in a possible range of 4, p<.01). Withdrawal scores for anxiety, craving, difficulty concentrating, impatience, and restlessness significantly decreased. Depressed mood, increased appetite, and irritability did not change. Order of flavor preference was peppermint over cinnamon over plain. Acceptability and ratings for sensory characteristics were favorable, and OT-NIC was well tolerated with no serious adverse effects. In conclusion, OT-NIC showed promise as a potential new aid for smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745495     DOI: 10.1080/1462220031000073270

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  6 in total

1.  Smokeless tobacco reduction with the nicotine lozenge and behavioral intervention.

Authors:  Jon O Ebbert; Amanda Edmonds; Xianghua Luo; Joni Jensen; Dorothy K Hatsukami
Journal:  Nicotine Tob Res       Date:  2010-06-04       Impact factor: 4.244

2.  Transdermal nicotine-induced tobacco abstinence symptom suppression: nicotine dose and smokers' gender.

Authors:  Sarah E Evans; Melissa Blank; Cynthia Sams; Michael F Weaver; Thomas Eissenberg
Journal:  Exp Clin Psychopharmacol       Date:  2006-05       Impact factor: 3.157

3.  The effect of acute exercise on cigarette cravings while using a nicotine lozenge.

Authors:  Amelia Tritter; Lyndsay Fitzgeorge; Harry Prapavessis
Journal:  Psychopharmacology (Berl)       Date:  2015-02-22       Impact factor: 4.530

4.  Effects of iontophoresis and chemical enhancers on the transport of lidocaine and nicotine across the oral mucosa.

Authors:  Ran Wei; Laurent Simon; Longsheng Hu; Bozena Michniak-Kohn
Journal:  Pharm Res       Date:  2011-12-02       Impact factor: 4.200

5.  Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette.

Authors:  Arthur L Brody; Mark A Mandelkern; Matthew R Costello; Anna L Abrams; David Scheibal; Judah Farahi; Edythe D London; Richard E Olmstead; Jed E Rose; Alexey G Mukhin
Journal:  Int J Neuropsychopharmacol       Date:  2008-08-18       Impact factor: 5.176

6.  Aqueous Extract of Semen Ziziphi Spinosae Exerts Anxiolytic Effects during Nicotine Withdrawal via Improvement of Amygdaloid CRF/CRF1R Signaling.

Authors:  Changhong Gu; ZhengLin Zhao; Xiaodong Zhu; Tong Wu; Bong Hyo Lee; Yu Jiao; Chul Won Lee; Dae Hwa Jung; Chae Ha Yang; Rongjie Zhao; Sang Chan Kim
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-02       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.